Carrick Therapeutics develops targeted cancer therapies that combine CDK12/13 inhibitors with existing oncology drugs to treat aggressive forms of breast, prostate, and ovarian cancers. Their approach addresses the challenge of treatment resistance in advanced cancer patients, aiming to improve clinical outcomes through innovative combination therapies.
Funding
$244.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many aggressive cancers develop resistance to existing oncology drugs, leading to treatment failure and poor outcomes for patients with advanced breast, prostate, ovarian, pancreatic, and Ewing's sarcoma. Overcoming this resistance requires novel therapeutic strategies that can effectively target the underlying mechanisms driving cancer progression.
Solution
Carrick Therapeutics develops combination therapies that pair CDK12/13 inhibitors with established oncology drugs to combat treatment resistance in aggressive cancers. Their approach focuses on addressing the unmet needs of patients with advanced breast, prostate, ovarian, pancreatic, and Ewing's sarcoma by targeting mechanisms of resistance. By combining novel CDK12/13 inhibitors with existing therapies, Carrick aims to improve clinical outcomes and provide more effective treatment options for patients facing these challenging cancers.
Target Audience
The primary target audience includes patients with advanced breast, prostate, ovarian, pancreatic, and Ewing's sarcoma, as well as clinicians and researchers focused on developing novel cancer therapies.
Features
- Development of novel therapies targeting aggressive and resistant forms of cancer.
- Focus on combination therapies involving CDK12/13 inhibitors and existing oncology drugs.
- Clinical trials evaluating Samuraciclib in combination with Vepdegestrant and Elacestrant for advanced breast cancer.
- CT7439, a first-in-class inhibitor of CDK12/13, undergoing Phase 1 clinical trial.
- Collaboration with pharmaceutical companies like Arvinas, Pfizer, and The Menarini Group to evaluate combination therapies.